{"id":"guanfacine-sustained-release","safety":{"commonSideEffects":[{"rate":"25-30","effect":"Somnolence"},{"rate":"15-20","effect":"Fatigue"},{"rate":"10-15","effect":"Headache"},{"rate":"8-12","effect":"Dizziness"},{"rate":"5-10","effect":"Hypotension"},{"rate":"5-8","effect":"Bradycardia"},{"rate":"5-10","effect":"Dry mouth"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Guanfacine selectively binds to alpha-2A adrenergic receptors in the brain, particularly in the prefrontal cortex, which decreases norepinephrine signaling and enhances working memory and executive function. The sustained-release formulation provides continuous receptor activation over 24 hours, allowing once-daily dosing. This mechanism makes it effective for attention-deficit/hyperactivity disorder (ADHD) and related conditions involving executive dysfunction.","oneSentence":"Guanfacine is an alpha-2A adrenergic receptor agonist that reduces norepinephrine activity in the prefrontal cortex to improve attention and impulse control.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:52.117Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT01146002","phase":"PHASE4","title":"Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine","status":"COMPLETED","sponsor":"Neurology Group of Bergen County, P.A.","startDate":"2010-06","conditions":"Attention-deficit/Hyperactivity Disorder","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Guanfacine (sustained release)","genericName":"Guanfacine (sustained release)","companyName":"Neurology Group of Bergen County, P.A.","companyId":"neurology-group-of-bergen-county-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Guanfacine (sustained release) is a small molecule used to treat Attention-deficit/Hyperactivity Disorder (ADHD). It is administered to improve language-based learning skills in individuals with ADHD.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}